Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
Patent 5719132 Issued on February 17, 1998. Estimated Expiration Date: June 27, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
514/50, 2,4-diketone pyrimidine or derivative (e.g., uracil, etc.)514/274, Chalcogen bonded directly to pyrimidine at 2-position536/28.55, Halogen bonded directly to the 5-position of the diazine ring (e.g., 5-fluorouridine, etc.)544/309, At 2-position and at 4- or 6-position544/310, Additional hetero ring which is unsaturated544/313Halogen attached directly to the diazine ring by nonionic bonding
The present invention is directed to the use of pharmaceutical compositions containing anti-retroviral effective amounts of (a) d4T and (b) 5-fluorouracil or a prodrug, or salt thereof.
Other References
S.D. Malley, et al, "Suppression of HIV Production in Resting Lymphocytes by Combining Didanosine and Hydroxamate Compounds," The Lancet, vol. 343, p. 1292, May 21, 1994
M.R. Posner, et al, "High-Dose Intravenous Zidovudine with 5-Fluorouracil and Leucovorin," Cancer, vol. 70, No. 12, pp. 2929-2934, Dec. 15, 1992
S.A. Riddler, et al, "Antiretroviral Activity of Stavudine (2',3'-Didehydro-3'-Deoxythymidine, D4T)," Antiviral Research, vol. 27, pp. 189-203, 1995
P.F. Lin, et al, "Genotypic and Phenotypic Analysis of Human Immunodeficiency Virus Type 1 Isolates from Patients on Prolonged Stavudine Therapy," J. Infect. Dis., vol. 170, pp. 1157-1164, 1994. (November)
W.-Y. Gao, et al, "Anti-Human Immunodeficiency Virus Type 1 Activity of Hydroxyurea in Combination with 2',3'-Dideoxynucleosides," Mol. Pharm., vol. 46, pp. 767-772, 1994
F. Lori, et al, "Hydroxyurea as an Inhibitor of Human Immunodeficiency Virus-Type 1 Replication," Science, vol. 266, pp. 801-805, (Nov. 4, 1994)
V.A. Johnson and R.E. Byington, "Quantitative Assays for Virus Infectivity," in A. Aldovini and B.D. Walker (Ed.), Techniques in HIV Research, Stockton Press, New York, pp. 71-76, 1990
S, Cox, et al, "Comparison of the Intracellular Metabolism of 3'-Azido-3'-Deoxythymidine and 3'-Fluoro-3'-Deoxythymidine in Lymphocytes in the Presence of 5-Fluoro-2'-Deoxyuridine," Antiviral Chemistry and Chemotherapy, vol. 1, No. 2, pp. 155-161, 1990
W.-Y. Gao, et al, "Low Levels of Deoxynucelotides in Peripheral Blood Lymphocytes: A Strategy to Inhibit Human Immunodeficiency Virus Type 1 Replication," Proc. Natl. Acad. Sci., vol. 90, pp. 8925-8928, Oct., 1993
J. Balzarini, et al, "2',3'-Dideoxycytidine: Regulation of its Metabolism and Anti-Retroviral Potency by Natural Pyrimidine Nucleogide Synthesis, and by Inhibitors of Pyrimidine Nucleotide Synthesis " Molecular Pharmacology, vol. 32, No. 6, pp. 798-806, Dec., 1987
M.N. Prichard, et al, "Inhibition of Thymidylate Synthase and Dihydrofolate Reductase Potentiate the Antiviral Effect of Acyclovir," Antiviral Research, vol. 20, pp. 249-259, 1993
F. Lori, et al, "Hydroxyurea Inhibits HIV-1 Replication by Inducing Low dNTP Levels. A Cellular Enzyme as a Target to Inhibit HIV-1," Antiviral Research, vol. 23, p. 63, 1994
W.-Y. Gao, et al, "Anti-HIV 1 Activity of Hydroxyurea in Combination with 2',3'-Dideoxynucleosides," Clinical Research, vol. 42, No. 2, p. 280A, 1994
Gong et al., "Potentiation of the Stavudine Anti-Human Immunodeficiency Virus Activity by 5-Fluorouracil," Antimicrobial Agents & Chemotherapy, 40(5), 1229 (May 1996)
Vila et al, "Absence of Viral Rebound After Treatment of HIV-Infected Patients with Didanosine ddI! and Hydroxycarbamide Hydroxyurea!," Lancet,350(9078), 635-636 (Aug. 30, 1997
June 27, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
